Last edition
News about "Ranluspec"
Lupin Receives US FDA Approval for Interchangeable Biosimilar Ranibizumab, Ranluspec
Lupin has secured US FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis, expanding its biosimilars portfolio and broadening access to treatments for retinal and vision-related disorders.
Ranluspec | 05/06/2026 | By News Bureau | 108
Lupin Secures European Commission Approval for Ranluspec, Biosimilar Ranibizumab
European Commission clears Lupin’s biosimilar ranibizumab, Ranluspec, for multiple retinal disorders; Sandoz to commercialise across the EU, expanding access to affordable biologics.
Ranluspec | 24/02/2026 | By News Bureau | 154
Lupin Secures Positive CHMP Opinion for Ranibizumab Biosimilar
Lupin has received a positive opinion from the CHMP for its ranibizumab biosimilar, supported by comprehensive analytical similarity data and a global Phase III clinical trial involving 600 patients with neovascular Age-related Macular Degeneration (AMD).
Ranluspec | 18/12/2025 | By News Bureau | 176
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy